$HCM News

HUTCHMED And Innovent Biologics Announce That The Joint New Drug Application For The Combination Of Elunate And Tyvyt Has Been Granted Approval By The China National Medical Products Administration

China Authority Accepts And Grants Priority Review To Hutchmed's Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia Patients Who Have Had An Insufficient Response To Prior Glucocorticoid Treatment

Reported Earlier, HUTCHMED Highlights HMPL-A580 Anti-Tumor Activity And Surufatinib Combination Therapy Data Ahead Of AACR Annual Meeting 2026 Presentations In San Diego

Reported Earlier, HUTCHMED Highlights HMPL-A580 Anti-Tumor Activity And Surufatinib Combination Therapy Data Ahead Of AACR Annual Meeting 2026 Presentations In San Diego

Reported Sunday, HUTCHMED Launches Phase III Clinical Trial Of Third-Generation BTK Inhibitor HMPL-760 With R-GemOx In Chinese Relapsed/Refractory Diffuse Large B-cell Lymphoma Patients

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ...

B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HUTCHMED Recalls Cancer Drug Tazverik in China After US Withdrawal Over Safety Risks

Hutchmed price target lowered to $21 from $22 at BofA

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

HUTCHMED H2 Earnings Call Highlights

HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript

HUTCHMED Reports 2025 Full Year Results and Business Updates

HUTCHMED (China) Limited 2025 Q4 - Results - Earnings Call Presentation

HUTCHMED (China) FY EPS $2.62 Beats $1.43 Estimate, Sales $548.512M Miss $591.425M Estimate

An Overview of HUTCHMED (China)'s Earnings

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

HUTCHMED Doses First Patient In Global Phase I/IIa Trial Of PI3K/PIKK-EGFR Conjugate HMPL-A580 For Advanced Solid Tumors In China And US